Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Celecoxib shows surprising activity against estrogen receptors
December 28th, 2004
Six months of treatment with celecoxib (Celebrex; Pfizer Inc.) in women at risk of developing breast cancer results in the reduction of estrogen receptor (ER) expression in breast cells, a research team at The University of Texas M.D. Anderson Cancer Center has found. The surprising insight - that celecoxib may regulate a cell's use of estrogen - could help explain the drug's observed anticancer properties, says the study's lead author, Banu Arun, MD, associate professor in the Department of Breast Medical Oncology. "Since estrogen receptor expression is a marker of proliferation, this finding confirms celecoxib's antiproliferative properties," she...
Source: Cancer Weekly (2004-12-28)
|
